logo
Brazil touts 'positive' call with senior U.S. trade official

Brazil touts 'positive' call with senior U.S. trade official

Reuters07-03-2025

BRASILIA, March 6 (Reuters) - Brazilian Vice President Geraldo Alckmin on Thursday held a "positive" video call with U.S. Commerce Secretary Howard Lutnick that focused in part on U.S. tariff policy, the vice president's office said.
Lutnick is one of U.S. President Donald Trump's top trade advisers while Alckmin also serves as the South American country's trade, industry and development minister.
Trump announced earlier this year 25% tariffs on imports of steel and aluminum, which are expected to take effect on March 12.
The South American country is one of the largest sources of U.S. steel imports, having exported 4.3 million metric tons to the U.S. last year, or about 48% of its shipments, according to Brazil's government data.
Lutnick said during the call that he would pass along to Trump a request from Alckmin to postpone the tariffs, a source from the Brazilian government told Reuters.
According to a statement from Alckmin's office, which did not mention a request on potentially postponing tariffs, the dialogue between the two governments should continue in order to reach an understanding on tariffs and other issues.
Brazilian news website G1 reported, citing sources, that Lutnick told Alckmin the U.S. could postpone the tariffs on Brazilian goods.
Further bilateral talks are planned over the next few days, Alckmin's statement added, noting that United States Trade Representative, Jamieson Greer, was also on the call.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Reuters

time28 minutes ago

  • Reuters

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.

US wholesale inventories in April revised higher
US wholesale inventories in April revised higher

Reuters

time2 hours ago

  • Reuters

US wholesale inventories in April revised higher

WASHINGTON, June 9 (Reuters) - U.S. wholesale inventories increased in April amid stockpiling of prescription medication in anticipation of tariffs from the Trump administration. Stocks at wholesalers rose 0.2% instead of being unchanged, as estimated last month, the Commerce Department's Census Bureau said on Monday. Economists polled by Reuters had expected last month's estimate would be unrevised. Inventories, a key part of gross domestic product, climbed 0.3% in March. They advanced 2.3% on a year-over-year basis in April. Wholesale stocks of prescription medication surged 1.3% in April. There were also increases in apparel, motor vehicle, groceries and professional equipment inventories. President Donald Trump has said he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients. Apart from drugmakers, businesses front-loaded imports in the first quarter, seeking to avoid Trump's sweeping duties on foreign goods, resulting in a large trade deficit that subtracted a record 4.90 percentage points from GDP. The front-running faded in April, leading to a record decline in imports and the overall trade deficit. While the contraction in the deficit at face value suggests trade could significantly add to gross domestic product in the second quarter, economists say some of the boost could be offset by low inventories. Inventory accumulation increased at a rate of $163.0 billion in the first quarter. The economy contracted at a 0.2% annualized rate in the January-March period, the first GDP decline in three years. It grew at a 2.4% pace in the fourth quarter. Sales at wholesalers edged up 0.1% in April after jumping 0.8% in March. At April's sales pace it would take wholesalers 1.30 months to clear shelves, unchanged from March.

Erik ten Hag tried to STOP Man Utd signing Antony but club ‘pushed £86million transfer through at all costs'
Erik ten Hag tried to STOP Man Utd signing Antony but club ‘pushed £86million transfer through at all costs'

Scottish Sun

time3 hours ago

  • Scottish Sun

Erik ten Hag tried to STOP Man Utd signing Antony but club ‘pushed £86million transfer through at all costs'

Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) ERIK TEN HAG tried to block Manchester United from signing mega-money flop Antony, according to a sensational claim. Antony, 25, joined the Red Devils in 2022 for £85.5million in Ten Hag's first summer at the club to follow the manager directly from Ajax. Sign up for Scottish Sun newsletter Sign up 3 A sensational claim from the co-founder of Erik ten Hag's SEG agency has claimed he tried to block Antony's transfer to Man Utd Credit: Richard Pelham / The Sun 3 The claim says Man Utd 'pushed through the deal at all costs' Credit: AFP The Old Trafford outfit originally did not want to pay as much for the star. However, according to widespread reports, Man Utd only pushed ahead with the deal after being encouraged by Ten Hag to complete it when he lost his first two games in charge. Then Man Utd chief John Murtough submitted three bids to take Antony from the Dutch giants, which was eventually accepted. And after a bright start, Antony failed to live up to his billing and quickly became a scapegoat for Ten Hag's failings as a Man Utd boss. READ MORE IN FOOTBALL OUT THE BLUE Chelsea release four stars including member of Conference League final squad The Brazilian eventually lost his place in the starting XI in his second season before he was sent out on loan to Real Betis halfway through his third season with Man Utd. Ten Hag now manages Bayer Leverkusen and has been linked with the winger once again. But in a stunning claim from Kees Vos, co-founder of Sports Entertainment Group (SEG) who are Ten Hag's agency, he says Ten Hag actually tried to BLOCK the move, with Man Utd being the ones wanting to "push it through at all costs". Writing in the book, Liverpool and the Dutch, Vos claims: "Ten Hag and Vos were not in favour of this and wanted to stop the transfer. BEST ONLINE CASINOS - TOP SITES IN THE UK "But the club wanted to push through at all costs, because Arsenal was also interested in Antony. "The risk of a stronger competitor would be great. Ultimately, Manchester United paid almost 100 million euros for Antony. 'With you, I started to smile again' - Tearful Antony announces Real Betis exit "Although Ten Hag did not support this transfer, it stuck with him throughout his entire time in Manchester that he took over the attacker from Ajax for this ill-fated amount, who was never able to fulfil his promise." Overall, Antony scored just 12 goals and added five assists in 96 games for the Red Devils and was often ridiculed for his flagrant skills which often yielded no end product. His loan at La Liga club Betis reminded people of skills as he contributed to 14 goals in 26 games. Man Utd chiefs are reportedly willing to take a hit worth more than half of what they originally paid in order to get him off the books, with a figure of around £40m being reported. SunSport have also revealed how Ten Hag's Bayer are considering a move for Jack Grealish after he was told his Manchester City career is over. 3 Join SUN CLUB for the Man Utd Files every Thursday plus in-depth coverage and exclusives from Old Trafford WATCH EVERY MATCH OF THE CLUB WORLD CUP 2025 LIVE ON DAZN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store